{"id":2054,"date":"2023-04-06T07:23:14","date_gmt":"2023-04-06T07:23:14","guid":{"rendered":"https:\/\/voxzogopatient-pprd-001.azurewebsites.net\/en-us\/?page_id=2054"},"modified":"2026-06-23T20:34:18","modified_gmt":"2026-06-23T20:34:18","slug":"how-voxzogo-works","status":"publish","type":"page","link":"https:\/\/www.voxzogo.com\/en-us\/how-voxzogo-works\/","title":{"rendered":"Why VOXZOGO"},"content":{"rendered":"
In people with achondroplasia<\/span>, the FGFR3<\/span> cell signals are overactive, leading to inhibited bone growth throughout the body. VOXZOGO<\/span> targets the cause of inhibited bone growth by mimicking the body’s natural cell signals<\/strong> to improve the balance of cell signaling.<\/p>\n Learn more about treatment with VOXZOGO.<\/p>\n Download Brochure<\/a><\/p>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n This graphic is an illustration of the cell signaling imbalance in achondroplasia and how VOXZOGO is designed to improve the balance. This graphic is not to scale and does not reflect a percentage growth.<\/small><\/p>\n CNP<\/span><\/strong>, C-type natriuretic peptide; FGFR3<\/span><\/strong>, fibroblast growth factor receptor 3.<\/small><\/p>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n VOXZOGO<\/span> is the first and only treatment FDA approved from birth<\/strong> to increase linear growth* *Linear growth, an increase in length or height, is one indicator of overall health and development.<\/small><\/p>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n Satya and his son Vivan, 18 years old, started VOXZOGO at 8 years old until his growth plates closed<\/p>\n\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t – Satya, Vivan’s father<\/p>\n\t\t\t\t <\/div>\n \t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n <\/div>\n <\/div>\n<\/div>\n\n BioMarin provided funding for the International consensus guidelines on the implementation and monitoring of vosoritide therapy in individuals with achondroplasia<\/em>, including payment to participants. BioMarin was not involved in deciding the guidelines content, including who were involved in developing the guidelines. For details, please see the Acknowledgements section of the publication.<\/p>\n <\/div>\n \n Backed by 10+ years of clinical trial<\/span> experience in achondroplasia.<\/p>\n \n \n Your local BioMarin representative can help you find answers.<\/p>\n \n
<\/div>\n <\/figure>\n <\/div>\n <\/div>\n<\/div>\n\nBones only grow for a limited time<\/h2>\n
\nfor children with achondroplasia while they are still growing (before growth plates<\/span> have closed).<\/p>\n“My advice would be to start early—as early as possible to take
full advantage of the growth phase.”<\/h2>\n
Medical guidelines support starting VOXZOGO early, with treatment until bones stop growing.<\/h3>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n
<\/div>\n
<\/div>\n <\/div>\n <\/figure>\n <\/div>\n \t\t<\/div>\n\t<\/div>\n<\/div>\n\nAsk your child’s doctor about starting VOXZOGO as early as possible
to help give them the most time possible to benefit from treatment.<\/h3>\n \n <\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n
Results with VOXZOGO<\/h3>\n \n
Explore the Data <\/a>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n
Looking for more information about VOXZOGO?<\/h2>\n <\/div>\n